ViP, The Effects of Rofecoxib (Trade Name Vioxx) in Reducing the Risk of Prostate Cancer
Sponsor
Merck
Description
ViP study is a double-blinded, randomized, placebo-controlled trial evaluating the effects of rofecoxib 25mg compared with placebo in decreasing the incidence of capsular and extracapsular prostate cancer in men with initially elevated risk.
